Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 14.6% in December

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 474,300 shares, a drop of 14.6% from the November 30th total of 555,600 shares. Currently, 23.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 660,100 shares, the short-interest ratio is currently 0.7 days.

Sunshine Biopharma Trading Down 0.3 %

Sunshine Biopharma stock opened at $3.06 on Monday. The stock has a 50-day moving average price of $2.81 and a two-hundred day moving average price of $2.15. Sunshine Biopharma has a 12 month low of $2.11 and a 12 month high of $599.80. The company has a market capitalization of $3.75 million, a PE ratio of -0.02 and a beta of 1.42.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.00 by ($9.94). Sunshine Biopharma had a negative net margin of 12.82% and a negative return on equity of 17.89%. The business had revenue of $8.44 million during the quarter.

Analysts Set New Price Targets

Separately, Aegis reiterated a “buy” rating and set a $15.00 price target on shares of Sunshine Biopharma in a report on Thursday, December 5th.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.